Intranasal influenza A virus H5N1 vaccine - ProStrakan

Drug Profile

Intranasal influenza A virus H5N1 vaccine - ProStrakan

Alternative Names: Intranasal H5N1 vaccine - Archimedes

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Archimedes Pharma
  • Developer Kyowa Kirin International
  • Class Influenza A vaccines; Vaccines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in United Kingdom (Intranasal)
  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 08 Jun 2010 Phase-I clinical trials in Influenza-A virus H5N1 subtype in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top